Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
10Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
BioMarin Pharmaceutical Inc. (BMRN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
3Distinct source URLs
9High confidence
0.790Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from CAMP graph: ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license…
FOLD
Amicus Therapeutics Inc
72%
Reciprocal relationship from FOLD graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from FOLD graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from FOLD g…
Reciprocal relationship from LLY graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. …
Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYN…
Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: suance of the Avenue Warrant on March 9, 2026, the shares into which the Ave…
Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabil…
Reciprocal relationship from TRDA graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and …
BioMarin Pharmaceutical Inc. Customers
Ticker
Name
Confidence
Evidence
AMICUS-THERAPEUTICS-INC
AMICUS-THERAPEUTICS-INC
92%
Under the Merger Agreement, receipt of the French FDI Clearance satisfies the final condition to the Merger other than conditions that by their nature are to be satisfied at the closing of the Merger.
SANOFI
SANOFI
92%
As of March 31, 2026, and December 31, 2025, the accounts receivable balance for Sanofi included $ 152.6 million and $ 148.0 million, respectively, of unbilled accounts receivable, which becomes paya…
SNYNF
Sanofi
92%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYN…
Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB g…
INOZYME-PHARMA-INC
INOZYME-PHARMA-INC
85%
ternal innovation. In April 2026, we acquired Amicus Therapeutics, Inc. (Amicus) to expand and diversify our rare disease product portfolio (the Amicus Acquisition). In addition, in July 2025 we acqu…
FOLD
Amicus Therapeutics Inc
72%
Reciprocal relationship from FOLD graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from FOLD graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from FOLD g…
SNYNF
Sanofi
72%
and timing of orders in countries that place large government orders; and • VOXZOGO: higher sales volume from new patients initiating therapy across all regions. These increases were partially offset…
Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabil…
Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…
Reciprocal relationship from CRS graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from CRS graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from CRS grap…
BioMarin Pharmaceutical Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BMRN-DEBT
Debt stack $4.2B
90%
Market cache reports total debt of $4.2B.
BMRN-DEBT-8287
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
BioMarin Pharmaceutical Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioMarin Pharmaceutical Inc..
BioMarin Pharmaceutical Inc. Ownership
Holder
Name
Confidence
Evidence
BMRN-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 560 tracked holders.
BioMarin Pharmaceutical Inc. Extended Supply Chain Network
